Actualités iShares Core Moderate Allocation ETF - AOM | Actions American Stock Exchange

Business software firm ActiveOps raises GBP76 million in AIM float

ActiveOps PLC said Thursday it has raise GBP75.7 million gross for selling shareholders in its initial public offerin ...

Koronis Pharmaceuticals Appoints Stephen Becker, M.D., Chief Medical Officer

SEATTLE, Oct. 26 /PRNewswire/ -- Koronis Pharmaceuticals, Inc. today announced the appointment of Stephen Becker, M.D., as chief medical...

Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond

Agreement Eliminates Development Milestones, Significantly Reduces Royalties and Restructures Sublicense Provisions SOUTH SAN FRANCISCO, Calif...

AnorMED shares begin trading on NASDAQ

VANCOUVER, Sept. 7 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that its common shares will begin trading on...

AnorMED Board recommends shareholders reject hostile Genzyme offer and not tender shares

VANCOUVER, Sept. 5 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) announced that its Board of...

AnorMED advises shareholders to take no action on unsolicited takeover bid from Genzyme Corporation

VANCOUVER, Sept. 1 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM; TSX:AOM) today confirmed that Genzyme Corp...

Genzyme to Initiate Tender Offer to Acquire AnorMED, Inc.

Proposed Acquisition Will Add Complementary Late-Stage Transplant Product CAMBRIDGE, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Genzyme...

AnorMED rejects unsolicited approach from Genzyme

Considers Genzyme Proposal Undervalued VANCOUVER, Aug. 30 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (AMEX:AOM;...

AnorMED announces NASDAQ listing and filing of shelf registration statement

VANCOUVER, Aug. 28 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM;TSX:AOM) today announced that it has received approval from the NASDAQ Stock...

AnorMED announces Annual and Special Meeting of Shareholders

VANCOUVER, Aug. 28 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM;TSX:AOM) today announced that it has called the Company's 2006 Annual and...

AnorMED reports fiscal 2007 first quarter results and upcoming milestones

Increased loss result of previously announced one-time charges LANGLEY, BC, July 27 /PRNewswire-FirstCall/ -- AnorMED (TSX:AOM, AMEX:AOM) today...

AnorMED to present at the Orion Healthcare Conference

VANCOUVER, June 20 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that William J. Adams, Chief Financial Officer...

AnorMED provides outlook for fiscal 2007

Releases financial results for fiscal year ended March 31, 2006 LANGLEY, BC, June 13 /PRNewswire-FirstCall/ -- AnorMED (TSX:AOM, AMEX:AOM) today...

AnorMed to present at the fifth annual Needham Biotechnology Conference

VANCOUVER, June 9 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that the Company will participate at the Needham...

AnorMED to present at the Pacific Growth Equities Life Sciences Conference

VANCOUVER, June 8 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that the Company will participate at the Pacific...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

iShares Core Moderate Allocation ETF (AOM)

Outils de qualité professionnelle, pour des investisseurs individuels.

AOM Actualités

Business software firm ActiveOps raises GBP76 million in AIM float

Koronis Pharmaceuticals Appoints Stephen Becker, M.D., Chief Medical Officer

Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond

AnorMED shares begin trading on NASDAQ

AnorMED Board recommends shareholders reject hostile Genzyme offer and not tender shares

AnorMED advises shareholders to take no action on unsolicited takeover bid from Genzyme Corporation

Genzyme to Initiate Tender Offer to Acquire AnorMED, Inc.

AnorMED rejects unsolicited approach from Genzyme

AnorMED announces NASDAQ listing and filing of shelf registration statement

AnorMED announces Annual and Special Meeting of Shareholders

AnorMED reports fiscal 2007 first quarter results and upcoming milestones

AnorMED to present at the Orion Healthcare Conference

AnorMED provides outlook for fiscal 2007

AnorMed to present at the fifth annual Needham Biotechnology Conference

AnorMED to present at the Pacific Growth Equities Life Sciences Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

iShares Core Moderate Allocation ETF (AOM) Actualités

iShares Core Moderate Allocation ETF (AOM)

Outils de qualité professionnelle, pour des investisseurs individuels.

AOM Actualités

Business software firm ActiveOps raises GBP76 million in AIM float

Koronis Pharmaceuticals Appoints Stephen Becker, M.D., Chief Medical Officer

Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond

AnorMED shares begin trading on NASDAQ

AnorMED Board recommends shareholders reject hostile Genzyme offer and not tender shares

AnorMED advises shareholders to take no action on unsolicited takeover bid from Genzyme Corporation

Genzyme to Initiate Tender Offer to Acquire AnorMED, Inc.

AnorMED rejects unsolicited approach from Genzyme

AnorMED announces NASDAQ listing and filing of shelf registration statement

AnorMED announces Annual and Special Meeting of Shareholders

AnorMED reports fiscal 2007 first quarter results and upcoming milestones

AnorMED to present at the Orion Healthcare Conference

AnorMED provides outlook for fiscal 2007

AnorMed to present at the fifth annual Needham Biotechnology Conference

AnorMED to present at the Pacific Growth Equities Life Sciences Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application